Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals

Novo Nordisk's stock price declined on Monday following the company's announcement of 2030 targets. The pharmaceutical company manufactures Ozempic and other weight-loss medications. Investors had anticipated different guidance or performance projections from the announcement.

Next story